SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 13D Under the Securities Exchange Act of 1934

(Amendment No. 10)*

SCORPIUS HOLDINGS, INC.

(Name of Issuer)

Common Stock, Par Value \$0.0002 Per Share

(Title of Class of Securities)

42237K 409

(CUSIP Number)

Mr. Jeffrey Wolf Orion Holdings V, LLC Seed-One IV, LLC c/o Scoripus Holdings, Inc. 627 Davis Drive Morrisville, North Carolina 27560

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

May 13, 2024

(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of \$\$ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. \Box

NOTE: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 240.13d-7 for other parties to whom copies are to be sent.

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 42237	K 409	13D	Page 2 of 9 Pages	
(1)	NAME OF REPORTING PERSON			
	Jeffrey Wolf			
(2)	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP			
. ,	(a) 🗆			
(2)	(b) SECUSE ONLY			
(3)	SEC USE ONLY SOURCE OF FUNDS			
(1)				
	Not applicable			
(5)	Not Applicable	L PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS	S 2(d) OR 2(e) □	
(6)	CITIZENSHIP OR PLACE OF ORGA	ANIZATION		
NUMBER OF	United States of America (7) SOLE VOTING POWER			
SHARES	(7) SOLE VOTING FOWER			
BENEFICIALLY	4,104,922			
OWNED BY EACH				
REPORTING				
PERSON WITH				
	(8) SHARED VOTING POWER			
	21,256			
	(9) SOLE DISPOSITIVE POWE	R		
	4,104,922			
	(10) SHARED DISPOSITIVE PO	WER		
	21,256			
(11)	AGGREGATE AMOUNT BENEFICIALLY OWNED BY REPORTING PERSON			
	4,126,178			
(12)	, ,	UNT IN ROW (11) EXCLUDES CERTAIN SHARES		
(13)	PERCENT OF CLASS REPRESENTI	ED BY AMOUNT IN ROW (11)		
	10.5%			
(14)	TYPE OF REPORTING PERSON			
	IN			

CUSIP No. 42237	K 409	13D	Page 3 of 9 Page		
(1)	NAME OF REPORTING PERSON	NAME OF REPORTING PERSON			
	Orion Holdings V, LLC				
(2)	CHECK THE APPROPRIATE BOX	X IF A MEMBER OF A GROUP			
	(a) 🗆				
(2)	(b) □ SEC USE ONLY				
(3)	SOURCE OF FUNDS				
(4)	SOURCE OF TONDS				
	Not applicable				
(5)		GAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM	AS 2(d) OR 2(e) □		
(6)	Not Applicable CITIZENSHIP OR PLACE OF ORG	GANIZATION			
(0)	CITIZENSIIII OKTEMEE OF OK	STATES AT THE STATE OF THE STATES AT THE STA			
	Delaware				
NUMBER OF SHARES	(7) SOLE VOTING POWER				
BENEFICIALLY	0				
OWNED					
BY EACH					
REPORTING PERSON WITH					
	(8) SHARED VOTING POWE	ER			
	11.025				
	(9) SOLE DISPOSITIVE POW	/FR			
	() SOLL DISTOSITIVE FOR	, EK			
	0	ACMIED.			
	(10) SHARED DISPOSITIVE P	OWER			
	11,025				
(11)	AGGREGATE AMOUNT BENEFICIALLY OWNED BY REPORTING PERSON				
	11,025				
(12)	CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES				
(13)	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)				
	T 4 1 00/				
(14)	Less than 1.0% TYPE OF REPORTING PERSON				
(* *)	THE OF RELOCITING FERSON				
	OO (Limited Liability Company)				

CUSIP No. 42237	K 409		13D	Page 4 of 9	
(1)	NAM	IE OF REPORTING PERSON			
	Seed-	-One Holdings VI, LLC			
(2)	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP				
	(a) 🗆				
	(b) □				
(3)		USE ONLY			
(4)	SOU	RCE OF FUNDS			
		applicable			
(5)			PROCEEDINGS IS REQUIRED PURSUANT	TO ITEMS 2(d) OR 2(e) \square	
		Applicable			
(6)	CITIZ	ZENSHIP OR PLACE OF ORGAN	IZATION		
	Delay	ware			
NUMBER OF	(7)	SOLE VOTING POWER			
SHARES					
BENEFICIALLY OWNED		0			
BY EACH					
REPORTING					
PERSON WITH					
	(8)	SHARED VOTING POWER			
		10,231			
	(9)	SOLE DISPOSITIVE POWER			
		^			
	(10)	0 SHARED DISPOSITIVE POWI	FR		
	(10)				
(11)	10,231				
(11)	AGGREGATE AMOUNT BENEFICIALLY OWNED BY REPORTING PERSON				
	10,23	31			
(12)	CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES □				
(13)	PERO	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)			
	Less	than 1.0%			
(14)	TYPE OF REPORTING PERSON				
	OO (Limited Liability Company)				
	00 (Emined Endomity Company)			

CUSIP No. 42237I	ζ 409	13D	Page 5 of 9 Pages	
(1)	NAME OF REPORTING PERSON			
	Elusys Holdings Inc.			
(2)	CHECK THE APPROPRIATE BO	OX IF A MEMBER OF A GROUP		
	(a) □			
(3)	(b) □ SEC USE ONLY			
(4)	SOURCE OF FUNDS			
	Not applicable			
(5)		EGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d)	OR 2(e) □	
(6)	Not Applicable CITIZENSHIP OR PLACE OF O	RGANIZATION		
,0)	CITIZENSHIP OR PLACE OF ORGANIZATION			
	Delaware			
NUMBER OF SHARES	(7) SOLE VOTING POWER			
BENEFICIALLY	0			
OWNED				
BY EACH REPORTING				
PERSON WITH				
	(8) SHARED VOTING POV	VER		
	0			
	(9) SOLE DISPOSITIVE PO	WER		
	0			
	(10) SHARED DISPOSITIVE	POWER		
	0			
(11)	AGGREGATE AMOUNT BENEFICIALLY OWNED BY REPORTING PERSON			
	0			
(12)		MOUNT IN ROW (11) EXCLUDES CERTAIN SHARES □		
(13)	PERCENT OF CLASS REPRESE	ENTED BY AMOUNT IN ROW (11)		
	00.0%			
(14)	TYPE OF REPORTING PERSON	I		
	СО			

Item 1. Security and Issuer.

This Amendment No. 10 (this "Amendment No. 10") amends the Schedule 13D, dated July 29, 2013 (the "Original 13D"), Amendment No. 1 to the Original 13D, dated February 9, 2017 ("Amendment No. 1"), Amendment No. 2 to the Original 13D, dated March 7, 2017 ("Amendment No. 2"), Amendment No. 3 to the Original 13D, dated April 27, 2017 ("Amendment No. 3"), Amendment No. 4 to the Original 13 D, dated January 2, 2020 ("Amendment No. 4"), Amendment No. 5 to the Original 13D, dated January 4, 2021 ("Amendment No. 5"), Amendment No. 6 to the Original 13D, dated December 13, 2021 ("Amendment No. 6"), Amendment No. 7 to the Original 13D, dated December 30, 2022 ("Amendment No. 7"), Amendment No. 8 to the Original 13D, dated August 21, 2023 ("Amendment No. 8"), and Amendment No. 9, dated December 11, 2023, previously filed by the Reporting Persons (as defined below), as applicable. Mr. Wolf, Orion, Seed-One, and Elusys Holdings Inc. ("Elusys Holdings") are collectively referred to as the "Reporting Persons." Capitalized terms not defined herein shall have the respective meanings ascribed to them in the Original 13D, Amendment No. 1, Amendment No. 2, Amendment No. 3, Amendment No. 4, Amendment No. 5, Amendment No. 6, Amendment No. 7., Amendment No. 8 or Amendment No. 9. The class of equity securities to which this Amendment No. 10 relates is the Common Stock, of Scorpius Biosciences, Inc., a Delaware corporation (the "Company"). The principal executive offices of the Company are located at 627 Davis Drive, Morrisville, North Carolina 27560.

Item 3. Source and Amount of Funds or Other Consideration.

The information in Item 4 of this Schedule 13D is incorporated herein by reference.

Item 4. Purpose of Transaction.

Item 4 is hereby amended and supplemented as follows:

On May 13, 2024, Mr. Wolf indicated to the representative of the underwriters for the Company's proposed public offering that he was interested in purchasing 2,500,000 Units, each unit consisting of one share of the Company's common stock and one warrant to acquire one share of the Company's common stock, upon the same terms as the investors in the proposed offering.

<u>Item 5.</u> <u>Interest in Securities of the Issuer.</u>

Item 5 is hereby amended and supplemented as follows.

As of the date hereof, the aggregate number and percentage of shares of Common Stock deemed beneficially owned by the Reporting Persons (based on 36,031,964 shares of Common Stock outstanding as of May 9, 2023, and 60 days out for vesting of options,), are as follows:

(a) Common Shares deemed beneficially owned:

(i)	Mr.	Wolf:

- (ii) Orion:
- (iii) Seed-One:
- (iv) Elusys Holdings

*less than 1%

(b) Number of Common Shares as to which Mr. Wolf has:

- (i) Sole power to vote or to direct the vote: 4,104,922
- (ii) Shared power to vote or to direct the vote: 21,256
- (iii) Sole power to dispose or to direct the disposition of: 4,104,922
- (iv) Shared power to vote or to direct the disposition of: 21,256

Number of Common Shares as to which Orion has:

- (i) Sole power to vote or to direct the vote: 0
- (ii) Shared power to vote or to direct the vote: 11,025
- (iii) Sole power to dispose or to direct the disposition of: 0
- (iv) Shared power to vote or to direct the disposition of: 11,025

Number of Common Shares as to which Seed-One has:

- (i) Sole power to vote or to direct the vote: 0
- (ii) Shared power to vote or to direct the vote: 10,231
- (iii) Sole power to dispose or to direct the disposition of: 0
- (iv) Shared power to vote or to direct the disposition of: 10,231

Number of Common Shares as to which Elusys Holdings has:

- (i) Sole power to vote or to direct the vote: 0
- (ii) Shared power to vote or to direct the vote: 0
- (iii) Sole power to dispose or to direct the disposition of: 0
- (iv) Shared power to vote or to direct the disposition of: 0
- (c) None of the Reporting Persons effected any transactions in Common Stock during the 60 days prior to the date hereof.
- (d) Not applicable.
- (e) Not applicable.

Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.

The information in Items 2 and 4 of this Schedule 13D is incorporated herein by reference.

Percent of class of Common Shares:

10.5% *%

*%

*%

CUSIP No. 42237K 409	13D	Page 8 of 9 Pages
----------------------	-----	-------------------

<u>Item 7</u>. Material to Be Filed as Exhibits.

Item 7 is hereby amended and supplemented by adding the following:

Exhibit 1: Joint Filing Agreement, dated May 13, 2024

Form of Warrant (incorporated by reference to Exhibit 4.21 of the Company's Registration Statement on Form S-1 filed with the Securities and Exchange Commission on May 13, 2024). Exhibit 2:

CUSIP No. 42237K 409	13D	Page 9 of 9 Pages		
SIGNATURE				
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.				

Date: May 13, 2024

By: /s/ Jeffrey Wolf

Name: Jeffrey Wolf

ORION HOLDINGS V, LLC

By: /s/ Jeffrey Wolf

Name: Jeffrey Wolf Title: Managing Member

SEED-ONE HOLDINGS VI, LLC

By: /s/ Jeffrey Wolf

Name: Jeffrey Wolf Title: Managing Member

ELUSYS HOLDINGS INC.

By: /s/ Jeffrey Wolf

Name: Jeffrey Wolf

Title: Chief Executive Officer

JOINT FILING AGREEMENT

This JOINT FILING AGREEMENT, is dated as of May 13, 2024, and is by and among Jeffrey Wolf, Orion Holdings V, LLC, a Delaware limited liability company ("Orion"), Seed-One Holdings VI, LLC, a Delaware limited liability company ("Seed-One"), and Elusys Holdings Inc., a Delaware corporation ("Elusys Holdings," and collectively with Mr. Wolf, Orion, and Seed-One, the "Reporting Persons").

WHEREAS, pursuant to Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), the parties hereto desire to satisfy any filing obligation under Section 13(d) of the Exchange Act by a single joint filing;

NOW, THEREFORE, in consideration of the premises and the mutual covenants herein contained, the Reporting Persons hereby agree and represent as follows:

- 1. Amendment No. 10 to Schedule 13D with respect to the Common Stock, par value \$0.0002 per share, of Scorpius Biosciences, Inc. (to which this Joint Filing Agreement is an exhibit) is filed on behalf of each of the Reporting Persons.
- 2. Each of the Reporting Persons is responsible for the timely filing of Schedule 13D and any amendments thereto, and for the completeness and accuracy of the information concerning such Person contained therein, provided that each such Person is not responsible for the completeness or accuracy of the information concerning any of the other Reporting Persons, unless such Person knows or has reason to believe that such information is inaccurate.

IN WITNESS WHEREOF, the undersigned have caused this Joint Filing Agreement to be duly executed and delivered as of the date first above written.

By: /s/ Jeffrey Wolf

Name: Jeffrey Wolf

ORION HOLDINGS V, LLC

By: /s/ Jeffrey Wolf

Name: Jeffrey Wolf Title: Managing Member

SEED-ONE HOLDINGS VI, LLC

By: /s/ Jeffrey Wolf

Name: Jeffrey Wolf Title: Managing Member

ELUSYS HOLDINGS INC.

By: /s/ Jeffrey Wolf

Name: Jeffrey Wolf

Title: Chief Executive Officer